News | July 27, 2025
Dr. Reddy’s infuses Rs. 565 crore in its Russian subsidiary
The company has made an investment of Rs. 565.40 crore in DRL Russia for a total equity stake of 45.19%
The company has made an investment of Rs. 565.40 crore in DRL Russia for a total equity stake of 45.19%
Laurus Labs has reported total income of Rs. 1,580 crores during the period ended June 30, 2025
Solara Active Pharma Sciences has reported total income of Rs. 320.13 crores during the period ended June 30, 2025
_256_384.jpg)
Cipla has reported total income of Rs. 7,216.03 crores during the period ended June 30, 2025
The scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs
Revenue increased 11.4 per cent to Rs. 8,545 crore
Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population
European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Phosphate-based excipients provide higher bulk densities and enable the reduction of the tablet sizes
Subscribe To Our Newsletter & Stay Updated
